

EAGLE PHARMACEUTICALS, INC.

Form 8-K

February 20, 2015

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**  
**of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **February 13, 2015**

**Eagle Pharmaceuticals, Inc.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction  
of incorporation)

**001-36306**  
(Commission File Number)

**20-8179278**  
(IRS Employer Identification No.)

**50 Tice Boulevard, Suite 315**

**Woodcliff Lake, NJ**  
(Address of principal executive offices)

**07677**  
(Zip Code)

Registrant's telephone number, including area code: **(201) 326-5300**

## Edgar Filing: EAGLE PHARMACEUTICALS, INC. - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 1.01 Entry into a Material Definitive Agreement**

*Exclusive License Agreement*

On February 13, 2015, Eagle Pharmaceuticals, Inc. (the *Company*), entered into an exclusive license agreement (the *License*) with Cephalon, Inc., a wholly-owned subsidiary of Teva Pharmaceutical Industries Ltd. (*Teva*), for U.S. and Canadian rights to the *Company*'s bendamustine hydrochloride (HCl) rapid infusion product for treatment of patients with chronic lymphocytic leukemia and patients with indolent B-cell non-Hodgkin lymphoma. Under the *License*, the *Company* will be responsible for obtaining and maintaining all U.S. regulatory approvals and conducting post-approval clinical studies. *Teva* will be responsible for all U.S. commercial activities for the product including promotion and distribution, and is committed to specified minimum promotional and detailing efforts in connection with the commercialization of the product. In addition, *Teva* will, in consultation with the *Company*, be responsible for the prosecution, maintenance and enforcement of patents covering the product. The *Company* and *Teva* may subsequently agree to expand the development and commercialization of the product into Canada. Under the terms of the *License*, the *Company* will receive an upfront cash payment of \$30.0 million, and is eligible to receive up to \$90.0 million in additional milestone payments. In addition, the *Company* will receive double digit royalty payments on net sales of the product, assuming FDA approval. In connection with the *License*, the *Company* and *Teva* will enter into an interim supply agreement, pursuant to which the *Company* will be responsible for supplying product to *Teva* for a specified period while *Teva* or a third party second-source supplier is qualified.

The *License* may be terminated by either party for the other party's breach or bankruptcy. *Teva* may terminate the *License* for the *Company*'s failure to meet specific diligence standards in connection with obtaining regulatory approval for the product, in which case, the *Company* will be required to make a one-time termination payment to *Teva*, or for safety concerns or convenience. The *Company* may terminate the *License* if, by a specified date, certain milestones for the product have not been obtained or achieved and certain generic bendamustine products are launched in the U.S., provided that upon such termination, the *Company* will be required to make a one-time termination payment to *Teva*. The *Company* may also terminate the *License* if *Teva* challenges the *Company*'s patents on the product or the *Company*'s ready-to-dilute product. Rights to the product revert to the *Company* upon a termination.

*Settlement Agreement*

In connection with the entry into the *License*, on February 13, 2015 the *Company* and Cephalon entered into a settlement agreement (the *Settlement Agreement*), pursuant to which the parties agreed to settle the pending patent infringement claims against each other regarding *Teva*'s US Patent No. 8,791,270. In addition, under the *Settlement Agreement*, *Teva* granted the *Company* a non-exclusive, royalty-bearing license to market the *Company*'s bendamustine ready-to-dilute product in the U.S. after May 1, 2016.

The foregoing descriptions of the *License* and the *Settlement Agreement* are only summaries and are qualified in their entirety by reference to the respective agreement. The *Company* intends to file copies of the *License* and the *Settlement Agreement* as exhibits to its Quarterly Report on Form 10-Q for its fiscal quarter ending March 31, 2015, or as exhibits to an amendment to this Current Report on Form 8-K, portions of which will be subject to a FOIA Confidential Treatment Request to the Securities and Exchange Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended, for certain portions of the *License* and the *Settlement Agreement*. The omitted material will be included in the request for confidential treatment.



**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Eagle Pharmaceuticals, Inc.**

Dated: February 20, 2015

By: /s/ Scott Tarriff  
Scott Tarriff  
*President and Chief Executive Officer*